Literature DB >> 26451274

Optimization of Landscape Phage Fusion Protein-Modified Polymeric PEG-PE Micelles for Improved Breast Cancer Cell Targeting.

Tao Wang1, Valery A Petrenko2, Vladimir P Torchilin1.   

Abstract

Amphiphilic landscape phage fusion proteins with high affinity and selectivity towards breast cancer MCF-7 (Michigan Cancer Foundation-7) cells self-assemble with polymeric PEG-PE conjugates to form mixed micelles (phage-micelles) capable of cancer cell-targeted delivery of poorly-soluble drugs. While the PEG corona provides the stability and longevity to the micelles, its presence is a potential steric difficulties for the interaction of phage fusion protein with cell surface targets. We attempted to address this problem by controlling the length of the PEG block and the phage fusion protein quantity, selecting the optimal ones to produce a reasonable retention of the targeting affinity and selectivity of the MCF-7-specific phage fusion protein. Three PEG-PE conjugates with different PEG lengths were used to construct phage- and plain-micelles, followed by FACS analysis of the effect of the PEG length on their binding affinity and selectivity towards target MCF-7 cells using either a MCF-7 cell monoculture or a cell co-culture model composed of target cancer MCF-7 cells and non-target, non-cancer C166 cells expressing GFP (Green Fluorescent Protein). Both, the length of PEG and quantity of phage fusion protein had a profound impact on the targetability of the phage-micelles. Phage-micelles prepared with PEG2k-PE achieved a desirable binding affinity and selectivity. Incorporation of a minimal concentration of phage protein, up to 0.5%, produced maximal targeting efficiency towards MCF-7 cells. Overall, phage-micelles with PEG2k-PE and 0.5% of phage protein represent the optimal formulation for targeting towards breast cancer cells.

Entities:  

Keywords:  Breast cancer; Drug delivery; Landscape phage fusion protein; PEG-PE; Phage display; Polymeric micelles; Tumor targeting

Year:  2012        PMID: 26451274      PMCID: PMC4594861          DOI: 10.4172/2157-7439.S4-008

Source DB:  PubMed          Journal:  J Nanomed Nanotechnol


  34 in total

1.  On the mechanism of targeting of phage fusion protein-modified nanocarriers: only the binding peptide sequence matters.

Authors:  Tao Wang; Nikita Kulkarni; Gerard G M D'Souza; Valery A Petrenko; Vladimir P Torchilin
Journal:  Mol Pharm       Date:  2011-07-29       Impact factor: 4.939

2.  Cytoplasmic delivery of liposomes into MCF-7 breast cancer cells mediated by cell-specific phage fusion coat protein.

Authors:  Tao Wang; Shenghong Yang; Valery A Petrenko; Vladimir P Torchilin
Journal:  Mol Pharm       Date:  2010-08-02       Impact factor: 4.939

3.  Enhanced binding and killing of target tumor cells by drug-loaded liposomes modified with tumor-specific phage fusion coat protein.

Authors:  Tao Wang; Gerard G M D'Souza; Deepa Bedi; Olusegun A Fagbohun; L Prasanna Potturi; Brigitte Papahadjopoulos-Sternberg; Valery A Petrenko; Vladimir P Torchilin
Journal:  Nanomedicine (Lond)       Date:  2010-06       Impact factor: 5.307

Review 4.  Functionalized micellar systems for cancer targeted drug delivery.

Authors:  Damon Sutton; Norased Nasongkla; Elvin Blanco; Jinming Gao
Journal:  Pharm Res       Date:  2007-03-24       Impact factor: 4.200

Review 5.  Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs.

Authors:  Christopher J H Porter; Natalie L Trevaskis; William N Charman
Journal:  Nat Rev Drug Discov       Date:  2007-03       Impact factor: 84.694

6.  Landscape phage fusion protein-mediated targeting of nanomedicines enhances their prostate tumor cell association and cytotoxic efficiency.

Authors:  Prashanth K Jayanna; Deepa Bedi; James W Gillespie; Patricia DeInnocentes; Tao Wang; Vladimir P Torchilin; Richard C Bird; Valery A Petrenko
Journal:  Nanomedicine       Date:  2010-02-04       Impact factor: 5.307

7.  Accumulation of protein-loaded long-circulating micelles and liposomes in subcutaneous Lewis lung carcinoma in mice.

Authors:  V Weissig; K R Whiteman; V P Torchilin
Journal:  Pharm Res       Date:  1998-10       Impact factor: 4.200

8.  Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies.

Authors:  Tae-You Kim; Dong-Wan Kim; Jae-Yong Chung; Sang Goo Shin; Sung-Chul Kim; Dae Seog Heo; Noe Kyeong Kim; Yung-Jue Bang
Journal:  Clin Cancer Res       Date:  2004-06-01       Impact factor: 12.531

9.  A novel formulation of VIP in sterically stabilized micelles amplifies vasodilation in vivo.

Authors:  H Onyüksel; H Ikezaki; M Patel; X P Gao; I Rubinstein
Journal:  Pharm Res       Date:  1999-01       Impact factor: 4.200

10.  Exogenous Molecular Probes for Targeted Imaging in Cancer: Focus on Multi-modal Imaging.

Authors:  Bishnu P Joshi; Thomas D Wang
Journal:  Cancers (Basel)       Date:  2010-06-11       Impact factor: 6.639

View more
  6 in total

1.  Paclitaxel-loaded PEG-PE-based micellar nanopreparations targeted with tumor-specific landscape phage fusion protein enhance apoptosis and efficiently reduce tumors.

Authors:  Tao Wang; Shenghong Yang; Leslie A Mei; Chirag K Parmar; James W Gillespie; Kulkarni P Praveen; Valery A Petrenko; Vladimir P Torchilin
Journal:  Mol Cancer Ther       Date:  2014-09-19       Impact factor: 6.261

2.  Recent developments in protein and peptide parenteral delivery approaches.

Authors:  Ashaben Patel; Kishore Cholkar; Ashim K Mitra
Journal:  Ther Deliv       Date:  2014-03

Review 3.  Phage protein-targeted cancer nanomedicines.

Authors:  V A Petrenko; P K Jayanna
Journal:  FEBS Lett       Date:  2013-11-20       Impact factor: 4.124

Review 4.  Landscape Phage: Evolution from Phage Display to Nanobiotechnology.

Authors:  Valery A Petrenko
Journal:  Viruses       Date:  2018-06-07       Impact factor: 5.048

5.  Enhanced tumor delivery and antitumor activity in vivo of liposomal doxorubicin modified with MCF-7-specific phage fusion protein.

Authors:  Tao Wang; William C Hartner; James W Gillespie; Kulkarni P Praveen; Shenghong Yang; Leslie A Mei; Valery A Petrenko; Vladimir P Torchilin
Journal:  Nanomedicine       Date:  2013-09-09       Impact factor: 5.307

Review 6.  Drug delivery vectors based on filamentous bacteriophages and phage-mimetic nanoparticles.

Authors:  Zhigang Ju; Wei Sun
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.